An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations

Abstract

Introduction: In previous studies, we have shown that a gliclazide–cholic acid derivative (G–CA) mixture resulted in an enhanced ileal permeation of G (ex vivo). When administered orally to diabetic rats, it brought about a significant hypoglycaemic effect. In this study, we aim to create a novel microencapsulated-formulation of G–CA with uniform and coherent structure that can be further tested in our rat model of type 1 diabetes (T1D). We also aim to examine the effect of CA addition to G microcapsules in the morphology, structure and excipients’ compatibility of the newly designed microcapsules.

Method: Microencapsulation was carried out using our Buchi-based microencapsulating system developed in our laboratory. Using sodium alginate (SA) polymer, both formulations were prepared: G–SA (control) and G–CA–SA (test) at a constant ratio (1:3:30), respectively. Complete characterizations of microcapsules were carried out.

Results: The new G–CA–SA formulation is further optimized by the addition of CA exhibiting pseudoplastic-thixotropic rheological characteristics. Bead size remains similar after CA addition, the new microcapsules show no chemical interactions between the excipients and this was supported further by the spectral studies suggesting bead stability.

Conclusion: The new microencapsulated-formulation has good and uniform structural properties and may be suitable for oral delivery of antidiabetic-bile acid formulations.

• Artificial-cell microencapsulation
• bile acids
• diabetes
• gliclazide

Acknowledgements

The authors acknowledge the CHIRI at Curtin University, and the Curtin-seeding grant for the support and also acknowledge the use of equipment, scientific and technical assistance of the Curtin University Electron Microscope Facility, which has been partially funded by the University, State and Commonwealth Governments. The authors also acknowledge the Pharmaceutical Technology Laboratory and the contribution and intellectual input of Emeritus Professor Bruce Sunderland (Curtin School of Pharmacy).

Declaration of interest

The authors report no declarations of interest.